168 related articles for article (PubMed ID: 20155405)
1. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.
Ustaalioglu BB; Seker M; Bilici A; Canpolat N; Yıldirim E; Kefeli U; Ustaalioglu R; Yilmaz BE; Salepci T; Ozdemir N; Gumus M
Med Oncol; 2011 Mar; 28(1):258-64. PubMed ID: 20155405
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Zhen ZJ; Sun XF; Xia Y; Wang ZH; Ling JY
Ai Zheng; 2006 Apr; 25(4):471-5. PubMed ID: 16613683
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
4. Cervical lymph node hyperplasia on [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography scan after treatment of children and adolescents with malignant lymphoma.
Hu YY; Zhang X; Long W; Lin XP; Zhang YR; Li YH; Xiao ZZ; Zheng RL; Liang PY; Fan W
Eur J Radiol; 2015 Jul; 84(7):1378-82. PubMed ID: 25882963
[TBL] [Abstract][Full Text] [Related]
5. Role of flourine-18 fluorodeoxyglucose positron emission tomography in thymic pathology.
El-Bawab H; Al-Sugair AA; Rafay M; Hajjar W; Mahdy M; Al-Kattan K
Eur J Cardiothorac Surg; 2007 Apr; 31(4):731-6. PubMed ID: 17293120
[TBL] [Abstract][Full Text] [Related]
6. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
7. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma.
Zinzani PL; Tani M; Trisolini R; Fanti S; Stefoni V; Alifano M; Castellucci P; Musuraca G; Dalpiaz G; Alinari L; Marchi E; Fina M; Pellegrini C; Farsad M; Cancellieri A; Busca A; Canini R; Pileri S; Baccarani M; Boaron M
Haematologica; 2007 Jun; 92(6):771-7. PubMed ID: 17550849
[TBL] [Abstract][Full Text] [Related]
8. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
[TBL] [Abstract][Full Text] [Related]
9. Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma.
Franke FC; Damek A; Steglich J; Kurch L; Hasenclever D; Georgi TW; Wohlgemuth WA; Mauz-Körholz C; Körholz D; Kluge R; Landman-Parker J; Wallace WH; Fosså A; Vordermark D; Karlen J; Fernández-Teijeiro A; Cepelova M; Klekawka T; Attarbaschi A; Ceppi F; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Moellers M; Buerke B; Stoevesandt D
Pediatr Blood Cancer; 2023 Aug; 70(8):e30421. PubMed ID: 37243889
[TBL] [Abstract][Full Text] [Related]
10. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
14. Reactive thymic hyperplasia following chemotherapy for children with lymphoma: computed tomography may be able to provide valuable information to avoid over-treatment.
Tian L; Cai PQ; Cui CY; Mo YX; Gong X; Fan W
Eur J Cardiothorac Surg; 2015 May; 47(5):883-9. PubMed ID: 25079775
[TBL] [Abstract][Full Text] [Related]
15. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
Rodriguez M
Acta Radiol Suppl; 1998; 417():1-36. PubMed ID: 9645167
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
20. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas.
Hernandez-Pampaloni M; Takalkar A; Yu JQ; Zhuang H; Alavi A
Pediatr Radiol; 2006 Jun; 36(6):524-31. PubMed ID: 16622665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
